# US 2026/0218135 A1 · Use of rtl8-deficient cells to produce biocompatible, peg10-derived virus-like particles (vlp)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218135 A1
- Document ID: US20260218135A1
- Status: Published application
- Kind: A1
- Application number: 19/142,176
- Filed: 2023-12-15
- Published: 2026-07-30
- Earliest claimed: 2022-12-21
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, a body corporate
- Inventors: Alexandra Whiteley; William Campodonico-Burnett; Aaron Whiteley
- Web page: https://patentgrep.com/patent/US20260218135A1

## CPC

- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 5/0602: {Vertebrate cells}
- C12N 15/86: Viral vectors
- C12N 2510/00: Genetically modified cells
- C12N 2740/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/10023: Virus like particles [VLP]
- C12N 2740/10042: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2740/10051: Methods of production or purification of viral material
- C12N 2770/00023: Virus like particles [VLP]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to novel systems, methods, and compositions for increasing the production of virus-like particles (VLPs) in a cell. In particular, the invention includes disrupting the activity or expression of RTL8 and/or UBQLN2 in the cell, which causes an increase in PEG10 VLP formation.

## Claims

### Claim 1

A method of increasing production of virus-like particles (VLPs) in a cell, comprising the step of disrupting the activity or expression of RTL8, UBQLN2, or RTL8 and UBOLN2 in the cell, wherein said disruption causes an increase in PEG10 VLP formation.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cell comprises a human cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein said RTL8 comprises a nucleotide sequence selected from SEQ ID NO.'s 1-3, or a fragment or variant thereof, and wherein said UBQLN2 comprises a nucleotide sequence according to SEQ ID NO. 9, or a fragment or variant thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein said RTL8 comprises an amino acid sequence selected from SEQ ID NO.'s 4-7, or a fragment or variant thereof, and wherein said UBQLN2 comprises an amino acid sequence according to SEQ ID NO. 10, or a fragment or variant thereof.

### Claim 4 (depends on 1)

The method of claim 1, further comprising the step of expressing a heterologous nucleotide sequence, operably linked to a promoter, encoding a target mRNA, or gene editing RNA or peptide.

### Claim 5 (depends on 4)

The method of claim 4, wherein said mRNA or gene editing RNA or peptide comprises a therapeutic mRNA that is configured to be coupled with said PEG10 VLP.

### Claim 6 (depends on 1)

The method of claim 1, wherein said step of disrupting the expression of and/or activity of RTL8 and/or UBQLN2 comprises the step of contacting the cell with a therapeutically effective amount of an agent that inhibits the activity or expression of RTL8, and/or UBQLN2, or homologs of RTL8, and UBQLN2.

### Claim 7 (depends on 6)

The method of claim 6, wherein said agent is selected from the group consisting of: a nucleic acid molecule, an antibody or a biologically active fragment thereof, and an aptamer.

### Claim 8 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule is selected from the group consisting of: an anti-sense oligonucleotide, an inhibitory RNA molecule, a DNA enzyme, and a ribozyme that specifically inhibits the expression or activity of RTL8, UBQLN2, or homologs of RTL8, and UBQLN2.

### Claim 9 (depends on 1)

The method of claim 1, wherein said step of disrupting the expression of and/or activity of RTL8 comprises the step of genetically modifying the cell to knock-out of knock-down RTL8, or UBQLN2 or homologs of RTL8, and UBOLN2.

### Claim 10 (depends on 1)

The method of claim 1, wherein said step of disrupting the expression of and/or activity of RTL8 comprises the step of genetically modifying the cell to generate one or mutations in RTL8, or UBQLN2 that decrease or inhibit its expression or activity.

### Claim 11 (depends on 1)

A PEG10 VLP produced by the method of claim 1.

### Claim 12 (depends on 11)

The PEG10 VLP of claim 11, wherein said PEG10 VLP is isolated.

### Claim at position 14

13-56. (canceled)
